Aspira Women's Health, Inc. (AWH)
| Market Cap | 518.87M |
| Revenue (ttm) | 4.93M |
| Net Income (ttm) | -20.12M |
| Shares Out | 108.66M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $4.51 |
| Previous Close | $4.60 |
| Change ($) | -0.09 |
| Change (%) | -1.96% |
| Day's Open | 4.60 |
| Day's Range | 4.40 - 4.65 |
| Day's Volume | 177,438 |
| 52-Week Range | 2.47 - 10.54 |
AUSTIN, Texas, July 27, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that it will report financial results for the se...
Aspira Women's Health (AWH) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) today announced its OVA1® risk assessment test for ovarian cancer in women with pelvic masses is considered medi...
AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in and present a...
Aspira (AWH) delivered earnings and revenue surprises of 79.17% and 6.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Conference call scheduled for today, May13 at 4:30 p.m. ET Conference call scheduled for today, May13 at 4:30 p.m. ET
New Team Addition Is a Thought Leader in Reimbursement and Diagnostics New Team Addition Is a Thought Leader in Reimbursement and Diagnostics
Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Below is a repost of an article from Benzina.com, which features Schaeffer's V.P.
Aspira (AWH) delivered earnings and revenue surprises of -1350.00% and 11.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call scheduled for today, March 25th at 4:30 p.m. ET Conference Call scheduled for today, March 25th at 4:30 p.m. ET
AUSTIN, Texas, March 25, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced it has entered into an agreement with Dana-Farb...
Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Ms. Nicole Sandford to its Boa...
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced management will participate and present in the 2...
Aspira will incorporate Management Recommendations from the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in the Aspira GenetiX report Aspira...
AUSTIN, Texas, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced the pr...
AUSTIN, Texas, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced it has...
These winners are positioned for gains even after COVID.
Aspira to participate in the 10 th Annual LifeSci Advisors Corporate Access Event and Biotech Showcase™ from January 6 – 15 th , 2021
AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Canto...
Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET
Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET
AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the secon...
AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that ...
Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus anti...
AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-ow...
AUSTIN, Texas, June 09, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join th...
Vermillion's (VRML) CEO Valerie Palmieri on Q1 2020 Results - Earnings Call Transcript
Conference Call scheduled for today, May 14th at 4:30 p.m. ET Conference Call scheduled for today, May 14th at 4:30 p.m. ET
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2019 Results - Earnings Call Transcript
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q3 2019 Results - Earnings Call Transcript
Vermillion's (VRML) CEO Valerie Palmieri on Q2 2019 Results - Earnings Call Transcript
Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2018 Results - Earnings Call Transcript
About AWH
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address crit... [Read more...]
| Industry Diagnostics & Research | Founded 1993 |
| CEO Valerie Palmieri | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol AWH |
Financial Performance
In 2020, AWH's revenue was $4.65 million, an increase of 2.49% compared to the previous year's $4.54 million. Losses were -$17.91 million, 17.5% more than in 2019.